KR102735275B1 - 바이러스성 색전술을 위한 조성물 및 방법 - Google Patents
바이러스성 색전술을 위한 조성물 및 방법 Download PDFInfo
- Publication number
- KR102735275B1 KR102735275B1 KR1020187001688A KR20187001688A KR102735275B1 KR 102735275 B1 KR102735275 B1 KR 102735275B1 KR 1020187001688 A KR1020187001688 A KR 1020187001688A KR 20187001688 A KR20187001688 A KR 20187001688A KR 102735275 B1 KR102735275 B1 KR 102735275B1
- Authority
- KR
- South Korea
- Prior art keywords
- virus
- tumor
- oncolytic
- composition
- embolization
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 216
- 230000010102 embolization Effects 0.000 title claims abstract description 158
- 238000000034 method Methods 0.000 title claims abstract description 100
- 230000003612 virological effect Effects 0.000 title description 41
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 230
- 239000011859 microparticle Substances 0.000 claims abstract description 120
- 244000309459 oncolytic virus Species 0.000 claims abstract description 119
- 238000009472 formulation Methods 0.000 claims abstract description 90
- 229920001477 hydrophilic polymer Polymers 0.000 claims abstract description 77
- 241000700618 Vaccinia virus Species 0.000 claims description 110
- 108090000623 proteins and genes Proteins 0.000 claims description 92
- 239000000499 gel Substances 0.000 claims description 89
- 230000000174 oncolytic effect Effects 0.000 claims description 84
- 239000002872 contrast media Substances 0.000 claims description 65
- 239000002245 particle Substances 0.000 claims description 59
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims description 44
- 210000002767 hepatic artery Anatomy 0.000 claims description 43
- 239000003795 chemical substances by application Substances 0.000 claims description 38
- 230000003073 embolic effect Effects 0.000 claims description 34
- 210000004185 liver Anatomy 0.000 claims description 34
- 108020004440 Thymidine kinase Proteins 0.000 claims description 28
- 210000004369 blood Anatomy 0.000 claims description 28
- 239000008280 blood Substances 0.000 claims description 28
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 26
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 26
- 201000011510 cancer Diseases 0.000 claims description 25
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 25
- 239000006260 foam Substances 0.000 claims description 23
- 241000124008 Mammalia Species 0.000 claims description 21
- 230000002792 vascular Effects 0.000 claims description 21
- NTHXOOBQLCIOLC-UHFFFAOYSA-N iohexol Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NTHXOOBQLCIOLC-UHFFFAOYSA-N 0.000 claims description 20
- 229920002472 Starch Polymers 0.000 claims description 16
- 235000019698 starch Nutrition 0.000 claims description 16
- 239000008107 starch Substances 0.000 claims description 16
- 108010010803 Gelatin Proteins 0.000 claims description 12
- 101800003344 Vaccinia growth factor Proteins 0.000 claims description 12
- 229920000159 gelatin Polymers 0.000 claims description 12
- 239000008273 gelatin Substances 0.000 claims description 12
- 235000019322 gelatine Nutrition 0.000 claims description 12
- 235000011852 gelatine desserts Nutrition 0.000 claims description 12
- 229960001025 iohexol Drugs 0.000 claims description 12
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims description 11
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims description 11
- 239000005090 green fluorescent protein Substances 0.000 claims description 11
- 229960004647 iopamidol Drugs 0.000 claims description 11
- XQZXYNRDCRIARQ-LURJTMIESA-N iopamidol Chemical compound C[C@H](O)C(=O)NC1=C(I)C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C1I XQZXYNRDCRIARQ-LURJTMIESA-N 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- 239000000017 hydrogel Substances 0.000 claims description 10
- -1 iobtiridol Chemical compound 0.000 claims description 10
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 8
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 8
- 229960004359 iodixanol Drugs 0.000 claims description 8
- NBQNWMBBSKPBAY-UHFFFAOYSA-N iodixanol Chemical compound IC=1C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(=O)C)CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NBQNWMBBSKPBAY-UHFFFAOYSA-N 0.000 claims description 8
- 230000017074 necrotic cell death Effects 0.000 claims description 8
- 108010005774 beta-Galactosidase Proteins 0.000 claims description 7
- 102000005936 beta-Galactosidase Human genes 0.000 claims description 7
- 208000011581 secondary neoplasm Diseases 0.000 claims description 7
- 102000000311 Cytosine Deaminase Human genes 0.000 claims description 6
- 108010080611 Cytosine Deaminase Proteins 0.000 claims description 6
- AMDBBAQNWSUWGN-UHFFFAOYSA-N Ioversol Chemical compound OCCN(C(=O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I AMDBBAQNWSUWGN-UHFFFAOYSA-N 0.000 claims description 6
- 108700019146 Transgenes Proteins 0.000 claims description 6
- DGAIEPBNLOQYER-UHFFFAOYSA-N iopromide Chemical compound COCC(=O)NC1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)N(C)CC(O)CO)=C1I DGAIEPBNLOQYER-UHFFFAOYSA-N 0.000 claims description 6
- XUHXFSYUBXNTHU-UHFFFAOYSA-N Iotrolan Chemical compound IC=1C(C(=O)NC(CO)C(O)CO)=C(I)C(C(=O)NC(CO)C(O)CO)=C(I)C=1N(C)C(=O)CC(=O)N(C)C1=C(I)C(C(=O)NC(CO)C(O)CO)=C(I)C(C(=O)NC(CO)C(O)CO)=C1I XUHXFSYUBXNTHU-UHFFFAOYSA-N 0.000 claims description 5
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims description 5
- BAQCROVBDNBEEB-UBYUBLNFSA-N Metrizamide Chemical compound CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C(=O)N[C@@H]2[C@H]([C@H](O)[C@@H](CO)OC2O)O)=C1I BAQCROVBDNBEEB-UBYUBLNFSA-N 0.000 claims description 5
- 229960005063 gadodiamide Drugs 0.000 claims description 5
- HZHFFEYYPYZMNU-UHFFFAOYSA-K gadodiamide Chemical compound [Gd+3].CNC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC(=O)NC HZHFFEYYPYZMNU-UHFFFAOYSA-K 0.000 claims description 5
- 229960005451 gadoteridol Drugs 0.000 claims description 5
- DPNNNPAKRZOSMO-UHFFFAOYSA-K gadoteridol Chemical compound [Gd+3].CC(O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1 DPNNNPAKRZOSMO-UHFFFAOYSA-K 0.000 claims description 5
- 229960000780 iomeprol Drugs 0.000 claims description 5
- NJKDOADNQSYQEV-UHFFFAOYSA-N iomeprol Chemical compound OCC(=O)N(C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NJKDOADNQSYQEV-UHFFFAOYSA-N 0.000 claims description 5
- 229960000824 iopentol Drugs 0.000 claims description 5
- IUNJANQVIJDFTQ-UHFFFAOYSA-N iopentol Chemical compound COCC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I IUNJANQVIJDFTQ-UHFFFAOYSA-N 0.000 claims description 5
- 229960002603 iopromide Drugs 0.000 claims description 5
- 229960003182 iotrolan Drugs 0.000 claims description 5
- 229960004537 ioversol Drugs 0.000 claims description 5
- 229960002611 ioxilan Drugs 0.000 claims description 5
- UUMLTINZBQPNGF-UHFFFAOYSA-N ioxilan Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCCO)=C(I)C(C(=O)NCC(O)CO)=C1I UUMLTINZBQPNGF-UHFFFAOYSA-N 0.000 claims description 5
- 208000021039 metastatic melanoma Diseases 0.000 claims description 5
- 229960000554 metrizamide Drugs 0.000 claims description 5
- 108010060309 Glucuronidase Proteins 0.000 claims description 4
- 102000053187 Glucuronidase Human genes 0.000 claims description 4
- 108010052090 Renilla Luciferases Proteins 0.000 claims description 4
- 230000003362 replicative effect Effects 0.000 claims description 4
- 108050001286 Somatostatin Receptor Proteins 0.000 claims 1
- 102000011096 Somatostatin receptor Human genes 0.000 claims 1
- 241000700605 Viruses Species 0.000 description 169
- 241001465754 Metazoa Species 0.000 description 78
- 238000002591 computed tomography Methods 0.000 description 75
- 210000004027 cell Anatomy 0.000 description 70
- 210000001519 tissue Anatomy 0.000 description 58
- 241000283973 Oryctolagus cuniculus Species 0.000 description 56
- 238000011282 treatment Methods 0.000 description 42
- 229920003023 plastic Polymers 0.000 description 40
- 239000004033 plastic Substances 0.000 description 40
- 210000001367 artery Anatomy 0.000 description 39
- 241000712079 Measles morbillivirus Species 0.000 description 35
- 238000002347 injection Methods 0.000 description 32
- 239000007924 injection Substances 0.000 description 32
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 26
- 241000700562 Myxoma virus Species 0.000 description 26
- 206010002091 Anaesthesia Diseases 0.000 description 24
- 102000006601 Thymidine Kinase Human genes 0.000 description 24
- 230000037005 anaesthesia Effects 0.000 description 24
- 238000002583 angiography Methods 0.000 description 24
- 208000015181 infectious disease Diseases 0.000 description 24
- 201000009030 Carcinoma Diseases 0.000 description 22
- 210000002376 aorta thoracic Anatomy 0.000 description 22
- 238000002474 experimental method Methods 0.000 description 22
- 239000007983 Tris buffer Substances 0.000 description 21
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 21
- 241000711975 Vesicular stomatitis virus Species 0.000 description 19
- 102000004169 proteins and genes Human genes 0.000 description 19
- 230000002238 attenuated effect Effects 0.000 description 18
- 210000005228 liver tissue Anatomy 0.000 description 18
- 235000018102 proteins Nutrition 0.000 description 18
- 238000012217 deletion Methods 0.000 description 17
- 230000037430 deletion Effects 0.000 description 17
- 238000012544 monitoring process Methods 0.000 description 17
- 210000004209 hair Anatomy 0.000 description 16
- 210000002966 serum Anatomy 0.000 description 16
- 238000002054 transplantation Methods 0.000 description 16
- 210000000689 upper leg Anatomy 0.000 description 16
- 241000700639 Parapoxvirus Species 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 230000010076 replication Effects 0.000 description 15
- 229940060693 tiletamine / zolazepam Drugs 0.000 description 15
- 229960005486 vaccine Drugs 0.000 description 15
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 15
- 229960001600 xylazine Drugs 0.000 description 15
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 14
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 14
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 238000003780 insertion Methods 0.000 description 14
- 230000037431 insertion Effects 0.000 description 14
- 229910052740 iodine Inorganic materials 0.000 description 14
- 239000011630 iodine Substances 0.000 description 14
- 230000002829 reductive effect Effects 0.000 description 14
- 210000004881 tumor cell Anatomy 0.000 description 14
- 210000003462 vein Anatomy 0.000 description 14
- 229940009456 adriamycin Drugs 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- 230000014509 gene expression Effects 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 210000005166 vasculature Anatomy 0.000 description 13
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 12
- 241000700635 Orf virus Species 0.000 description 12
- 238000013459 approach Methods 0.000 description 12
- 210000004204 blood vessel Anatomy 0.000 description 12
- 230000035772 mutation Effects 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 11
- 101150003725 TK gene Proteins 0.000 description 11
- 238000002560 therapeutic procedure Methods 0.000 description 11
- 230000001018 virulence Effects 0.000 description 11
- 241000701022 Cytomegalovirus Species 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 238000003384 imaging method Methods 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 10
- 230000002779 inactivation Effects 0.000 description 10
- 208000014018 liver neoplasm Diseases 0.000 description 10
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 9
- 206010019695 Hepatic neoplasm Diseases 0.000 description 9
- 201000005505 Measles Diseases 0.000 description 9
- 241000700625 Poxviridae Species 0.000 description 9
- 239000000853 adhesive Substances 0.000 description 9
- 230000001070 adhesive effect Effects 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- 238000002594 fluoroscopy Methods 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 238000001990 intravenous administration Methods 0.000 description 9
- 238000011587 new zealand white rabbit Methods 0.000 description 9
- 210000003491 skin Anatomy 0.000 description 9
- 230000004083 survival effect Effects 0.000 description 9
- 229940124597 therapeutic agent Drugs 0.000 description 9
- 238000012384 transportation and delivery Methods 0.000 description 9
- 208000019300 CLIPPERS Diseases 0.000 description 8
- 108010012236 Chemokines Proteins 0.000 description 8
- 230000003187 abdominal effect Effects 0.000 description 8
- 230000005856 abnormality Effects 0.000 description 8
- 210000001715 carotid artery Anatomy 0.000 description 8
- 208000021930 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids Diseases 0.000 description 8
- 230000018044 dehydration Effects 0.000 description 8
- 238000006297 dehydration reaction Methods 0.000 description 8
- 210000005069 ears Anatomy 0.000 description 8
- 210000005161 hepatic lobe Anatomy 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 239000011505 plaster Substances 0.000 description 8
- 229940069575 rompun Drugs 0.000 description 8
- 230000029812 viral genome replication Effects 0.000 description 8
- 238000005303 weighing Methods 0.000 description 8
- QYEFBJRXKKSABU-UHFFFAOYSA-N xylazine hydrochloride Chemical compound Cl.CC1=CC=CC(C)=C1NC1=NCCCS1 QYEFBJRXKKSABU-UHFFFAOYSA-N 0.000 description 8
- 102000019034 Chemokines Human genes 0.000 description 7
- 208000005156 Dehydration Diseases 0.000 description 7
- 208000000059 Dyspnea Diseases 0.000 description 7
- 206010013975 Dyspnoeas Diseases 0.000 description 7
- 101150076998 ICP34.5 gene Proteins 0.000 description 7
- 206010024264 Lethargy Diseases 0.000 description 7
- 206010028851 Necrosis Diseases 0.000 description 7
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 7
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 7
- 206010054094 Tumour necrosis Diseases 0.000 description 7
- 210000001015 abdomen Anatomy 0.000 description 7
- 230000000259 anti-tumor effect Effects 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 7
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 7
- 230000003203 everyday effect Effects 0.000 description 7
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 7
- 238000002513 implantation Methods 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 230000000977 initiatory effect Effects 0.000 description 7
- 210000002414 leg Anatomy 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000012188 paraffin wax Substances 0.000 description 7
- 210000003240 portal vein Anatomy 0.000 description 7
- 208000013220 shortness of breath Diseases 0.000 description 7
- 210000002845 virion Anatomy 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 6
- 241000700586 Herpesviridae Species 0.000 description 6
- 101100508081 Human herpesvirus 1 (strain 17) ICP34.5 gene Proteins 0.000 description 6
- 101150027249 RL1 gene Proteins 0.000 description 6
- 206010053648 Vascular occlusion Diseases 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 210000002950 fibroblast Anatomy 0.000 description 6
- 102000046157 human CSF2 Human genes 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 208000021331 vascular occlusion disease Diseases 0.000 description 6
- 102000053602 DNA Human genes 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- 108010050904 Interferons Proteins 0.000 description 5
- 102000014150 Interferons Human genes 0.000 description 5
- 206010046865 Vaccinia virus infection Diseases 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 229940127089 cytotoxic agent Drugs 0.000 description 5
- 230000003111 delayed effect Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000013161 embolization procedure Methods 0.000 description 5
- 210000002919 epithelial cell Anatomy 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000000415 inactivating effect Effects 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 150000003839 salts Chemical group 0.000 description 5
- 241001529453 unidentified herpesvirus Species 0.000 description 5
- 208000007089 vaccinia Diseases 0.000 description 5
- 101150023320 B16R gene Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 4
- 101100195053 Human herpesvirus 1 (strain 17) RIR1 gene Proteins 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 102220465800 Interferon-induced, double-stranded RNA-activated protein kinase_M11L_mutation Human genes 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 238000011529 RT qPCR Methods 0.000 description 4
- 101100316831 Vaccinia virus (strain Copenhagen) B18R gene Proteins 0.000 description 4
- 101100004099 Vaccinia virus (strain Western Reserve) VACWR200 gene Proteins 0.000 description 4
- 241000700647 Variola virus Species 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000005809 anti-tumor immunity Effects 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 230000010109 chemoembolization Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 210000002889 endothelial cell Anatomy 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 230000028709 inflammatory response Effects 0.000 description 4
- 239000002054 inoculum Substances 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 230000003472 neutralizing effect Effects 0.000 description 4
- 108020001162 nitroreductase Proteins 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000000770 proinflammatory effect Effects 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 230000010415 tropism Effects 0.000 description 4
- 210000005167 vascular cell Anatomy 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- 101710113110 B-cell receptor-associated protein 31 Proteins 0.000 description 3
- 101150046614 C15L gene Proteins 0.000 description 3
- 241000450599 DNA viruses Species 0.000 description 3
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 3
- 101100342273 Escherichia coli (strain K12) kilR gene Proteins 0.000 description 3
- 101000651211 Homo sapiens Transcription factor PU.1 Proteins 0.000 description 3
- 101710139711 IkB-like protein Proteins 0.000 description 3
- 102100037850 Interferon gamma Human genes 0.000 description 3
- 102100034170 Interferon-induced, double-stranded RNA-activated protein kinase Human genes 0.000 description 3
- 101710081123 Interleukin-27 subunit alpha Proteins 0.000 description 3
- 241000700563 Leporipoxvirus Species 0.000 description 3
- 101710169105 Minor spike protein Proteins 0.000 description 3
- 101710081079 Minor spike protein H Proteins 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 241000700629 Orthopoxvirus Species 0.000 description 3
- 101000836070 Rattus norvegicus Serine protease inhibitor A3L Proteins 0.000 description 3
- 101710142113 Serine protease inhibitor A3K Proteins 0.000 description 3
- 241000700584 Simplexvirus Species 0.000 description 3
- 102100020886 Sodium/iodide cotransporter Human genes 0.000 description 3
- 101100234922 Swinepox virus (strain Kasza) LAP gene Proteins 0.000 description 3
- 102100027654 Transcription factor PU.1 Human genes 0.000 description 3
- 101150085955 US11 gene Proteins 0.000 description 3
- 101100382200 Vaccinia virus (strain Ankara) MVA018L gene Proteins 0.000 description 3
- 101100382201 Vaccinia virus (strain Copenhagen) C7L gene Proteins 0.000 description 3
- 101100280283 Vaccinia virus (strain Copenhagen) F11L gene Proteins 0.000 description 3
- 101100382202 Vaccinia virus (strain Western Reserve) VACWR021 gene Proteins 0.000 description 3
- 101100280285 Vaccinia virus (strain Western Reserve) VACWR050 gene Proteins 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000007910 cell fusion Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000003511 endothelial effect Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 210000004969 inflammatory cell Anatomy 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 101150036274 kil gene Proteins 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 229910044991 metal oxide Inorganic materials 0.000 description 3
- 150000004706 metal oxides Chemical class 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 238000012379 oncolytic virotherapy Methods 0.000 description 3
- 230000005298 paramagnetic effect Effects 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 102220280369 rs1361460244 Human genes 0.000 description 3
- 102220059024 rs747802641 Human genes 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 108010013351 sodium-iodide symporter Proteins 0.000 description 3
- 108090000586 somatostatin receptor 2 Proteins 0.000 description 3
- 102000004052 somatostatin receptor 2 Human genes 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000001685 thyroid gland Anatomy 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 108700026220 vif Genes Proteins 0.000 description 3
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 2
- 101150006352 B18R gene Proteins 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- GRSZFWQUAKGDAV-KQYNXXCUSA-N IMP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-KQYNXXCUSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- ZCYVEMRRCGMTRW-AHCXROLUSA-N Iodine-123 Chemical compound [123I] ZCYVEMRRCGMTRW-AHCXROLUSA-N 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 102000004459 Nitroreductase Human genes 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 108090000637 alpha-Amylases Proteins 0.000 description 2
- 102000004139 alpha-Amylases Human genes 0.000 description 2
- 229940024171 alpha-amylase Drugs 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 230000034303 cell budding Effects 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 210000000448 cultured tumor cell Anatomy 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 231100000676 disease causative agent Toxicity 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 238000012239 gene modification Methods 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 238000010914 gene-directed enzyme pro-drug therapy Methods 0.000 description 2
- 230000005017 genetic modification Effects 0.000 description 2
- 235000013617 genetically modified food Nutrition 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000000185 hemagglutinin Substances 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 239000012642 immune effector Substances 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 235000013902 inosinic acid Nutrition 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 101150066555 lacZ gene Proteins 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 229940041323 measles vaccine Drugs 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 230000001839 systemic circulation Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 230000005909 tumor killing Effects 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 230000007501 viral attachment Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 108010001779 Ancrod Proteins 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000700663 Avipoxvirus Species 0.000 description 1
- 101150019032 B29R gene Proteins 0.000 description 1
- 101150118897 B8R gene Proteins 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241001455646 Buffalopox virus Species 0.000 description 1
- 101710117545 C protein Proteins 0.000 description 1
- 102100031092 C-C motif chemokine 3 Human genes 0.000 description 1
- 101710155856 C-C motif chemokine 3 Proteins 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700664 Capripoxvirus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 101710172503 Chemokine-binding protein Proteins 0.000 description 1
- 241000700628 Chordopoxvirinae Species 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000457515 Cynomys herpesvirus Species 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 241000251729 Elasmobranchii Species 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 102100023688 Eotaxin Human genes 0.000 description 1
- 101710139422 Eotaxin Proteins 0.000 description 1
- 229910052693 Europium Inorganic materials 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 description 1
- 101000829127 Homo sapiens Somatostatin receptor type 2 Proteins 0.000 description 1
- 241000928771 Horsepox virus Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241001502974 Human gammaherpesvirus 8 Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 101710197234 Inactive chemokine-binding protein Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 229940124862 Measles virus vaccine Drugs 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102100039373 Membrane cofactor protein Human genes 0.000 description 1
- 241000700559 Molluscipoxvirus Species 0.000 description 1
- 241000700627 Monkeypox virus Species 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000004503 Perforin Human genes 0.000 description 1
- 108010056995 Perforin Proteins 0.000 description 1
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010037868 Rash maculo-papular Diseases 0.000 description 1
- 241001068263 Replication competent viruses Species 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000711931 Rhabdoviridae Species 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 229940124269 Somatostatin receptor 2 agonist Drugs 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 241000700568 Suipoxvirus Species 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- RZCIEJXAILMSQK-JXOAFFINSA-N TTP Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 RZCIEJXAILMSQK-JXOAFFINSA-N 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 101150004676 VGF gene Proteins 0.000 description 1
- 241000881059 Vaccinia virus Wyeth Species 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 230000007416 antiviral immune response Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 238000011072 cell harvest Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000005101 cell tropism Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000010405 clearance mechanism Effects 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000001218 confocal laser scanning microscopy Methods 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000007799 cork Substances 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229960002918 doxorubicin hydrochloride Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229920002313 fluoropolymer Polymers 0.000 description 1
- 239000004811 fluoropolymer Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000000799 fusogenic effect Effects 0.000 description 1
- 210000000609 ganglia Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000004201 immune sera Anatomy 0.000 description 1
- 229940042743 immune sera Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000004692 intercellular junction Anatomy 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 108010070145 interleukin-18 binding protein Proteins 0.000 description 1
- 102000044166 interleukin-18 binding protein Human genes 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 229910021644 lanthanide ion Inorganic materials 0.000 description 1
- 229910052747 lanthanoid Inorganic materials 0.000 description 1
- 150000002602 lanthanoids Chemical class 0.000 description 1
- 229910052745 lead Inorganic materials 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 208000012965 maculopapular rash Diseases 0.000 description 1
- 230000005291 magnetic effect Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- MMIPFLVOWGHZQD-UHFFFAOYSA-N manganese(3+) Chemical compound [Mn+3] MMIPFLVOWGHZQD-UHFFFAOYSA-N 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000002941 microtiter virus yield reduction assay Methods 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000005088 multinucleated cell Anatomy 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 229940095293 mumps vaccine Drugs 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000006654 negative regulation of apoptotic process Effects 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 210000004882 non-tumor cell Anatomy 0.000 description 1
- 231100001160 nonlethal Toxicity 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 238000012633 nuclear imaging Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000010915 one-step procedure Methods 0.000 description 1
- 238000012634 optical imaging Methods 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 239000002907 paramagnetic material Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229930192851 perforin Natural products 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920002959 polymer blend Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000010491 poppyseed oil Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000011555 rabbit model Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000010110 radioembolization Effects 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 229960003131 rubella vaccine Drugs 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 210000003594 spinal ganglia Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 229950008461 talimogene laherparepvec Drugs 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 229910001428 transition metal ion Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 108010078742 trisacryl gelatin microspheres Proteins 0.000 description 1
- 230000037455 tumor specific immune response Effects 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 108091000036 uracil phosphoribosyltransferase Proteins 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000006648 viral gene expression Effects 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 238000000316 virotherapy Methods 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/763—Herpes virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A61K39/165—Mumps or measles virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24171—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562182383P | 2015-06-19 | 2015-06-19 | |
| US62/182,383 | 2015-06-19 | ||
| PCT/IB2016/000993 WO2017037523A1 (en) | 2015-06-19 | 2016-06-17 | Compositions and methods for viral embolization |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20180021083A KR20180021083A (ko) | 2018-02-28 |
| KR102735275B1 true KR102735275B1 (ko) | 2024-11-29 |
Family
ID=58186857
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020187001688A Active KR102735275B1 (ko) | 2015-06-19 | 2016-06-17 | 바이러스성 색전술을 위한 조성물 및 방법 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10517910B2 (https=) |
| EP (1) | EP3310383B1 (https=) |
| JP (1) | JP6827467B2 (https=) |
| KR (1) | KR102735275B1 (https=) |
| CN (1) | CN108025056B (https=) |
| AU (1) | AU2016313969B2 (https=) |
| ES (1) | ES2795010T3 (https=) |
| WO (1) | WO2017037523A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4122492A1 (en) | 2015-02-25 | 2023-01-25 | Memorial Sloan Kettering Cancer Center | Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors |
| KR20180006916A (ko) | 2015-04-17 | 2018-01-19 | 메모리얼 슬로안-케터링 캔서 센터 | 고형 종양에 대한 면역치료제로서 mva 또는 mva델타e3l의 용도 |
| CN108025056B (zh) | 2015-06-19 | 2022-01-14 | 新罗杰股份有限公司 | 用于病毒栓塞的组合物和方法 |
| JP7025339B2 (ja) | 2016-02-25 | 2022-02-24 | メモリアル スローン ケタリング キャンサー センター | 癌免疫療法のための、チミジンキナーゼの欠失を伴い、ヒトｆｌｔ３ｌまたはｇｍ－ｃｓｆの発現を伴うかまたは伴わない、複製可能な弱毒化ワクシニアウイルス |
| CN109152827B (zh) | 2016-02-25 | 2023-07-21 | 纪念斯隆凯特琳癌症中心 | 重组mva或表达人flt3l的mvaδe3l及其作为抗固体肿瘤的免疫治疗剂的用途 |
| KR102190326B1 (ko) * | 2016-07-21 | 2020-12-11 | 코오롱생명과학 주식회사 | 재조합 백시니아 바이러스 및 이의 용도 |
| EP3621646A4 (en) | 2017-05-12 | 2021-06-02 | Memorial Sloan Kettering Cancer Center | VACCINIA VIRUS MUTANTS FOR CANCER IMMUNOTHERAPY |
| CN109554353B (zh) * | 2017-09-26 | 2021-08-06 | 杭州康万达医药科技有限公司 | 分离的重组溶瘤痘病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途 |
| KR20190059421A (ko) * | 2017-11-23 | 2019-05-31 | 주식회사 바이오녹스 | 항암바이러스의 간동맥 투여를 이용한 간암 치료방법 |
| CA3106202A1 (en) | 2018-07-13 | 2020-01-16 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods of treating cancer with tnf expressing myxoma virus |
| BR112021004692A2 (pt) | 2018-09-15 | 2021-06-08 | Memorial Sloan Kettering Cancer Center | poxvírus recombinantes para imunoterapia de câncer |
| US20240024393A1 (en) * | 2019-01-25 | 2024-01-25 | Virocure, Inc. | Pharmaceutical composition for preventing or treating cancer, comprising squirrel fibroma virus and reovirus |
| JP2022520220A (ja) | 2019-02-14 | 2022-03-29 | イグナイト イミュノセラピー インク | 組換えワクシニアウイルスおよびその使用方法 |
| MX2022002547A (es) * | 2019-09-02 | 2022-05-18 | Univ Arizona State | Una nueva plataforma de virus oncoliticos para tratar canceres con virus myxoma. |
| DE102020101197A1 (de) * | 2020-01-20 | 2021-07-22 | Charité - Universitätsmedizin Berlin | Medizinprodukt zur Arzneimittelabgabe mit verstärkter Wirkung |
| TW202217002A (zh) | 2020-07-13 | 2022-05-01 | 法商傳斯堅公司 | 免疫抑制之治療 |
| WO2023213763A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab |
| WO2023213764A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf |
| CN116942888B (zh) * | 2023-09-11 | 2026-03-24 | 科睿驰（深圳）医疗科技发展有限公司 | 淀粉水凝胶栓塞微球及其制备方法 |
| WO2026041811A1 (en) | 2024-08-23 | 2026-02-26 | Transgene | Recombinant poxvirus and method for regulating the expression of toxic conditional gene products of said recombinant poxvirus in a producing cell |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030211165A1 (en) * | 2000-03-24 | 2003-11-13 | Jean-Marie Vogel | Microspheres for active embolization |
| US8980246B2 (en) * | 2005-09-07 | 2015-03-17 | Sillajen Biotherapeutics, Inc. | Oncolytic vaccinia virus cancer therapy |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5073627A (en) | 1989-08-22 | 1991-12-17 | Immunex Corporation | Fusion proteins comprising GM-CSF and IL-3 |
| JPH07509122A (ja) | 1992-04-08 | 1995-10-12 | ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ，アズ レプリゼンテッド バイ ザ セクレター，デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 野生型麻疹ウイルス糖タンパク質：ワクチンおよびその検出方法 |
| FR2736358B1 (fr) | 1995-07-05 | 1997-09-26 | Agronomique Inst Nat Rech | Virus myxomateux recombinant |
| AU8877098A (en) | 1997-09-05 | 1999-03-29 | Nycomed Imaging As | Polymer particles made of polyvinyl alcohol and comprising contrast agent for chemoembolization |
| FR2784580B1 (fr) * | 1998-10-16 | 2004-06-25 | Biosepra Inc | Microspheres de polyvinyl-alcool et procedes de fabrication de celles-ci |
| JP2004510724A (ja) * | 2000-10-06 | 2004-04-08 | ヤゴテック アーゲー | 分子量の低下した澱粉からなる微粒子中に埋め込まれた免疫学的活性物質を含むワクチン組成物 |
| DE03722131T1 (de) | 2002-05-09 | 2005-09-15 | Oncolytics Biotech, Inc., Calgary | Methode zur schmerzbekämpfung mit onkolytischen viren |
| EP2269619A1 (en) * | 2002-08-12 | 2011-01-05 | Jennerex Biotherapeutics ULC | Methods and compositions concerning poxviruses and cancer |
| KR101772375B1 (ko) * | 2005-09-07 | 2017-08-29 | 신라젠(주) | Ｇｍ-ｃｓｆ를 발현하는 폭스바이러스를 사용한 전이성 및/또는 전신 파종성 암의 전신 치료법 |
| JPWO2008105504A1 (ja) * | 2007-03-01 | 2010-06-03 | コスメディ製薬株式会社 | 経皮免疫製剤、その製造方法及びそれを用いた経皮免疫方法 |
| KR20080084528A (ko) * | 2007-03-15 | 2008-09-19 | 제네렉스 바이오테라퓨틱스 인크. | 종양살상형 백시니아 바이러스 암 치료 |
| BR112012005774B8 (pt) * | 2009-09-14 | 2023-02-14 | Jennerex Inc | uso de um inibidor de quinase antiangiogênico no tratamento de câncer |
| WO2011135734A1 (ja) * | 2010-04-28 | 2011-11-03 | 株式会社アルファ・ナノ・メディカ | ウイルスの複合体、それを含有する治療薬及び治療方法 |
| US9724421B2 (en) * | 2010-11-29 | 2017-08-08 | Centre Hospitalier Universitaire Vaudois | Chemoembolization composition comprising anti-angiogenic agents |
| KR101942237B1 (ko) * | 2011-01-04 | 2019-01-25 | 신라젠(주) | 종양 항원에 대한 항체의 생산 및 종양용해 우두 바이러스의 투여에 의한 종양 특이적 보체 의존적 세포독성의 생산 |
| EP2739293B1 (en) | 2011-08-05 | 2020-06-10 | SillaJen Biotherapeutics, Inc. | Methods and compositions for production of vaccina virus |
| WO2014031693A1 (en) * | 2012-08-20 | 2014-02-27 | Genelux Corporation | Compositions containing protein polymers and vaccinia virus, and methods of use thereof |
| US20140194370A1 (en) * | 2013-01-08 | 2014-07-10 | University Of Utah Research Foundation | Silk-elastin like protein polymers for embolization and chemoembolization to treat cancer |
| CN108025056B (zh) | 2015-06-19 | 2022-01-14 | 新罗杰股份有限公司 | 用于病毒栓塞的组合物和方法 |
| HK1255192A1 (zh) * | 2015-09-08 | 2019-08-09 | Sillajen, Inc. | 表达细胞因子和羧酸酯酶的修饰的溶瘤痘苗病毒及其使用方法 |
-
2016
- 2016-06-17 CN CN201680048316.5A patent/CN108025056B/zh active Active
- 2016-06-17 KR KR1020187001688A patent/KR102735275B1/ko active Active
- 2016-06-17 ES ES16840890T patent/ES2795010T3/es active Active
- 2016-06-17 WO PCT/IB2016/000993 patent/WO2017037523A1/en not_active Ceased
- 2016-06-17 JP JP2018517499A patent/JP6827467B2/ja active Active
- 2016-06-17 AU AU2016313969A patent/AU2016313969B2/en not_active Ceased
- 2016-06-17 US US15/738,034 patent/US10517910B2/en active Active
- 2016-06-17 EP EP16840890.4A patent/EP3310383B1/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030211165A1 (en) * | 2000-03-24 | 2003-11-13 | Jean-Marie Vogel | Microspheres for active embolization |
| US8980246B2 (en) * | 2005-09-07 | 2015-03-17 | Sillajen Biotherapeutics, Inc. | Oncolytic vaccinia virus cancer therapy |
Non-Patent Citations (1)
| Title |
|---|
| HEPATOLOGY, Vol. 48, No. 6, 2008* |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017037523A1 (en) | 2017-03-09 |
| ES2795010T3 (es) | 2020-11-20 |
| JP6827467B2 (ja) | 2021-02-10 |
| US20180303886A1 (en) | 2018-10-25 |
| EP3310383A4 (en) | 2019-02-27 |
| CA2990133A1 (en) | 2017-03-09 |
| CN108025056A (zh) | 2018-05-11 |
| EP3310383A1 (en) | 2018-04-25 |
| JP2018517778A (ja) | 2018-07-05 |
| HK1252004A1 (en) | 2019-05-10 |
| KR20180021083A (ko) | 2018-02-28 |
| EP3310383B1 (en) | 2020-02-19 |
| AU2016313969B2 (en) | 2021-12-23 |
| CN108025056B (zh) | 2022-01-14 |
| AU2016313969A1 (en) | 2018-02-15 |
| US10517910B2 (en) | 2019-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102735275B1 (ko) | 바이러스성 색전술을 위한 조성물 및 방법 | |
| Wollmann et al. | Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates | |
| US8227440B2 (en) | Use of Myxoma virus for the therapeutic treatment of cancer and chronic viral infection | |
| US12319931B2 (en) | Oncolytic virus expressing interferon and application therefor | |
| EP1121137B1 (en) | Method for killing tumor and tumor associated endothelial cells using adenoviral mutants | |
| CN101137748B (zh) | 粘液瘤病毒与雷帕霉素的组合在治疗性处理中的应用 | |
| Meerani et al. | Oncolytic viruses in cancer therapy | |
| CA2990133C (en) | Compositions and methods for viral embolization | |
| Kirn | Monthly Update: Oncologic, Endocrine & Metabolic: Replicating oncolytic viruses: An overview | |
| HK1252004B (en) | Compositions and methods for viral embolization | |
| Saha et al. | Viral oncolysis of glioblastoma | |
| CN100451109C (zh) | 重组1型单纯疱疹病毒及制备方法和应用 | |
| CN100379453C (zh) | 粘液瘤病毒在治疗癌症和慢性病毒感染中的用途 | |
| Bell et al. | HISTORY OF ONCOLYTIC VIRUSES | |
| HK1081099B (en) | Use of myxoma virus for therapeutic treatment of cancer and chronic viral infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20180118 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20210616 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20240220 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20241010 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20241125 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20241126 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |